18.10

1.17% 0.21

After Hours: 18.10

Novocure Ltd (NVCR)

Overview News Price History Option Chain Financials Why NVCR Down? Discussions Forecast

Novocure Ltd stock is traded at $18.10, with a volume of 2.58M. It is up +1.17% in the last 24 hours and up +71.08% over the past month. NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.

Previous Close:

$17.89

Open:

$17.87

24h Volume:

2.58M

Relative Volume:

1.29

Market Cap:

$2.10B

Revenue:

$674.41M

Net Income/Loss:

$-173.05M

P/E Ratio:

-11.80

EPS:

-1.5343

Net Cash Flow:

$-48.07M

1W Performance:

+6.91%

1M Performance:

+71.08%

6M Performance:

+52.61%

1Y Performance:

+4.14%

1-Day Range:

$17.85

$18.92

1-Week Range:

$15.40

$18.92

52-Week Range:

$9.82

$20.06

Novocure Ltd Stock (NVCR) Company Profile

Name

Novocure Ltd

Sector

Healthcare (1110)

Industry

Medical Devices (142)

Phone

44 (0)15 3475 6700

Address

NO. 4 THE FORUM, ST. HELIER

Employee

1,605

Twitter

@novocure

Next Earnings Date

2026-04-30

Latest SEC Filings

NVCR's Discussions on Twitter

Compare NVCR vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NVCR Novocure Ltd	18.10	2.07B	674.41M	-173.05M	-48.07M	-1.5343
ABT Abbott Laboratories	82.56	146.87B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	282.58	109.33B	25.27B	3.34B	4.57B	8.6358
MDT Medtronic Plc	74.54	97.77B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	53.37	80.16B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	77.17	46.04B	6.30B	1.07B	1.09B	1.8406

Novocure Ltd Stock (NVCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-25-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Jul-08-25	Initiated	Ladenburg Thalmann	Buy
Dec-02-24	Upgrade	Evercore ISI	In-line → Outperform
Oct-16-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-28-23	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-08-23	Upgrade	Piper Sandler	Neutral → Overweight
Aug-04-23	Initiated	SVB Securities	Outperform
Jul-31-23	Upgrade	Evercore ISI	Underperform → In-line
Jun-07-23	Upgrade	Wedbush	Underperform → Neutral
May-16-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight
Jan-06-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-05-23	Reiterated	H.C. Wainwright	Buy
Nov-29-22	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-24-22	Downgrade	Piper Sandler	Overweight → Neutral
Jul-05-22	Downgrade	Evercore ISI	In-line → Underperform
May-16-22	Initiated	H.C. Wainwright	Buy
Feb-08-22	Initiated	Loop Capital	Buy
Feb-02-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-20-22	Upgrade	Truist	Hold → Buy
Jan-03-22	Upgrade	Evercore ISI	Underperform → In-line
Jul-01-21	Downgrade	Mizuho	Buy → Neutral
Apr-14-21	Downgrade	Wedbush	Neutral → Underperform
Jan-25-21	Reiterated	Piper Sandler	Overweight
Sep-23-20	Initiated	Northland Capital	Outperform
Sep-18-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-17-20	Downgrade	Truist	Buy → Hold
Jun-01-20	Resumed	Oppenheimer	Perform
May-01-20	Downgrade	Oppenheimer	Outperform → Perform
Apr-09-20	Downgrade	Evercore ISI	In-line → Underperform
Mar-05-20	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-02-20	Downgrade	Evercore ISI	Outperform → In-line
Jul-29-19	Upgrade	SunTrust	Hold → Buy
Jul-26-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-26-19	Downgrade	Wedbush	Outperform → Neutral
Mar-20-19	Initiated	SunTrust	Hold
Nov-02-18	Downgrade	Wells Fargo	Outperform → Market Perform
Jul-16-18	Initiated	Evercore ISI	Outperform
Apr-18-18	Reiterated	Mizuho	Buy
Feb-23-18	Reiterated	Mizuho	Buy
May-24-17	Upgrade	Wells Fargo	Market Perform → Outperform
Jul-29-16	Reiterated	Wedbush	Outperform
Jan-19-16	Initiated	Barclays	Underweight
Dec-02-15	Initiated	Deutsche Bank	Hold

View All

Novocure Ltd Stock (NVCR) Latest News

May 09, 2026

A Look At NovoCure (NVCR) Valuation After Raised 2026 Revenue Guidance And Q1 Beat - simplywall.st

May 09, 2026

May 08, 2026

Soleus discloses 10.49M-share stake in NovoCure (NASDAQ: NVCR) - Stock Titan

May 08, 2026

Oncology Company Given Neutral Rating as Q1/26 Beat Sets Up Catalyst - Streetwise Reports

May 08, 2026

NovoCure Ltd (MEX:NVCRN) Stock Price & 30 Year Financial Data - GuruFocus

May 08, 2026

NovoCure Ltd (MEX:NVCRN) DCF Valuation - GuruFocus

May 08, 2026

NovoCure Ltd (MEX:NVCRN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

May 08, 2026

NovoCure Ltd (MEX:NVCRN) Stock Earnings Transcripts - GuruFocus

May 08, 2026

May 06, 2026

Oncology Co. Tests Advanced Cancer Treatments, Reports Q1 2026 Financial Results - Streetwise Reports

May 06, 2026

May 05, 2026

MSN Money - MSN

May 05, 2026

Why NovoCure (NVCR) Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher - Sahm

May 05, 2026

May 04, 2026

International Markets and NovoCure (NVCR): A Deep Dive for Investors - Yahoo Finance

May 04, 2026

Wells Fargo Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $17 - Moomoo

May 04, 2026

May 03, 2026

NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook - Sahm

May 03, 2026

May 02, 2026

NovoCure Limited Surges As Guidance Hike Fuels NVCR Rally - timothysykes.com

May 02, 2026

Here's What Analysts Are Forecasting For NovoCure Limited (NASDAQ:NVCR) After Its First-Quarter Results - Moomoo

May 02, 2026

NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance

May 02, 2026

May 01, 2026

Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $20 - Moomoo

May 01, 2026